EHAB

ANALYST NOTE: EHAB (Enhabit, Inc.) Date: 2026-06-13 Current Price: $13.80

1. Structural Readiness

Aggressive/Pre-Breakout Entry: — (Not actionable on setup alone; requires confirmation) Breakout Level: — (Pending confirmation of the structural high) Current Price: $13.80 Extension: — (No extension calculated as no breakout has occurred)

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Macro Thesis: None. Assessment: As of 2026-06-13, there is no named secular thesis driving this name. This is a tactical, setup-led opportunity. Conviction must be derived strictly from the quality of the structural setup (the forming coil) and the underlying business fundamentals, rather than a broader macro narrative. We are judging this name on its ability to execute its operational plan and the technical structure's readiness to break out, not on a pre-existing thematic tailwind.

3. Business Overview

Company: Enhabit, Inc. Industry: Healthcare / Home Health & Hospice Business Model: Enhabit operates as a U.S.-based provider of home healthcare and hospice services. The company generates revenue by delivering post-acute care to patients in their homes, focusing on cost-effective alternatives to institutional care.

Operational Highlights (Source: Earnings Transcript, 2025-11-07):

• Revenue & Profitability: Management provided full-year guidance for the fiscal year ending 2025, expecting revenue between $1.058 billion and $1.063 billion. Adjusted EBITDA guidance was raised to a range of $106 million to $109 million, and adjusted free cash flow guidance was increased to $53 million to $61 million.
• Operational Efficiency: The company reported a pilot program showing a decline in total visits per episode from approximately 15 to 13, indicating improved efficiency in care delivery.
• Network Expansion: The branch network is expanding rapidly, with 83 additional branches rolled out in October alone, with the remainder expected by the end of November.
• Volume Growth: Home health total admissions were up 3.6% year-over-year, with census increasing 3.7%. The company noted 7 straight quarters of sequential census growth.
• Service Scope: The company manages chronic conditions including diabetes, hypertension, arthritis, Alzheimer's, and spinal stenosis. Services include wound care, cardiac rehabilitation, infusion therapy, and comprehensive hospice support (pain control, palliative care, bereavement support).

4. Archetype and Conviction

Archetype: Deep Value Recovery Rationale: The name fits the "Deep Value Recovery" archetype based on the combination of a recovering operational trajectory (7 quarters of sequential census growth) and management's upward revision of full-year guidance (revenue, EBITDA, and FCF) in late 2025. The business appears to be transitioning from a period of restructuring or underperformance to a phase of stable growth and margin expansion.

Valuation & Fundamentals:

• Financial Spine: Forward consensus EPS is estimated at $0.60 for FY1 and $0.67 for FY2.
• Conviction Stack:
• *Thesis Strength:* Low (Tactical only, no macro tailwind).
• *Evidence Quality:* High (Management has provided specific, upwardly revised guidance and operational metrics).
• *Structural Quality:* Moderate (Forming coil indicates a base is being built, but the breakout is unconfirmed).
• *Rerating Potential:* Dependent on the successful execution of the branch rollout and the realization of the efficiency gains (visit reduction) projected in the 2025 guidance.

Volatility Context:

• Current ATR: 0.3% (Sub-threshold).
• Analysis: The current volatility is extremely low compared to the historical "sweet spot" (4–6%). This suggests the stock is in a period of consolidation or low interest, which is consistent with a "forming" coil. However, the low ATR implies that once a breakout occurs, the move could be sharp, but the current lack of volatility makes immediate sizing difficult without a confirmed catalyst.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• A confirmed daily close above the structural resistance (breakout level) with volume expansion.
• Continued sequential growth in census and admissions in the subsequent quarters post-2025.
• Further upward revisions to guidance in the 2026 reporting cycle.

What Would Invalidate the Case:

• A reversal in the trend of admissions or census growth (breaking the 7-quarter streak).
• Failure to execute the branch rollout or a significant increase in visit frequency per episode (reversing the efficiency gains).

Evidence Gaps:

• 2026 Performance Data: The evidence block contains 2025 guidance and 2026 company profile data, but lacks specific 2026 earnings results or guidance updates to confirm if the 2025 trajectory held through the first half of 2026.
• Competitive Landscape: No specific data on market share shifts or competitor activity is available in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: 7 straight quarters of sequential census growth; Management raised full-year adjusted EBITDA guidance to $106M-$109M; 83 new branches rolled out in October 2025; Decline in visits per episode from 15 to 13 indicating efficiency gains. Sizing hint: Position size should be conservative given the "forming" status and lack of confirmed breakout; treat as a watchlist candidate until structure confirms. Expected path: Management expects continued branch expansion and efficiency gains to drive revenue and margin growth; price likely to consolidate near current levels until a structural breakout occurs. Expected horizon: 3 to 6 months for structural confirmation or invalidation.